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Abstract 
 
The endocrine signaling governing nuclear receptor (NR) function has been known for several 
decades to play a crucial role in the onset and progression of several tumor types. Notably 
among these are the estrogen receptor (ER) in breast cancer and androgen receptor (AR) in 
prostate cancer. Other nuclear receptors may be involved in cancer progression including the 
peroxisome-proliferator activating receptor gamma (PPARƴ ), which has been implicated in 
breast, thyroid, and colon cancers. These NR are phylogenetically conserved modular 
transcriptional regulators, which like histones, undergo post-translational modification by 
acetylation, phosphorylation and ubiquitination. Importantly, the transcriptional activity of the 
receptors is governed by the coactivator p300, the activity of which is thought to be rate-limiting 
in the activity of these receptors. Histone acetyltransferases (HATs) and histone deacetylases 
(HDACs), modify histones by adding or removing an acetyl group from the ɛ amino group of 
lysines within an evolutionarily conserved lysine motif. Histone acetylation results in changes in 
chromatin structure in response to specific signals. These enzymes can also directly catalyze 
the NRs themselves, thus modifying signals at the receptor level. The post-translational 
modification of NR which is regulated by hormones, alters the NR function toward a growth 
promoting receptor. The deacetylation of NR is mediated by TSA-sensitive and NAD-
dependent deacetylases. The regulation of NR by NAD-dependent enzymes provides a direct 
link between intracellular metabolism and hormone signaling. 
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1. Epigenetics  
Histone modification promotes changes in chromatin structure that may effect genetic 
expression in a heritable manner without directly altering the genome. The term epigenetics 
was coined by Conrad Waddington in the 1940s. Originally, epigenetics referred to the study of 
the way in which genes and their products bring a phenotype into being [1]. The Waddington 
equation originally referred to an equation; that epigenesis + genetics = epigenetics. In this 
context, Waddington referred to a neoclassical embryology debate on epigenesis versus 
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preformationism. Current thinking has limited the notion of epigenetics to modifications in gene 
expression that do not involve changes in DNA nuclear sequences. The study of heritable 
changes in gene expression that occur without a change in DNA sequence have identified 
families of enzymes that modify DNA, histones and other proteins which indirectly impact gene 
expression. Other examples of epigenetic regulation in mammalian genomes such as X 
chromosome inactivation, imprinting, and aberrant methylation in neoplasia have been recently 
reviewed elsewhere [2,3]. The last decade has witnessed the cloning and functional 
characterization of many of the genes known to govern the post-translational modification of 
histones and DNA that govern epigenetic changes. Histone modification by acetylation, 
methylation, phosphorylation and sumoylation occurs in an integrated manner. Furthermore 
these enzymes have been shown to regulate the activity of non-histone proteins, including 
structural proteins, transcription factors and transport proteins. Histone acetylases which 
function to regulate gene expression independently of DNA sequence modulate the activity of 
diverse proteins including the nuclear receptors. The biological significance of histone 
acetylation and their function in nuclear receptor signaling will be reviewed in the context of 
human cancer and endocrine signaling. 
 
1.1. Histone acetylation and deacetylation  
The packaging of euchromatic DNA into nucleosomes involves an octamer of four core 
histones (H2A, H2B, H3 and H4). Posttranslational modification of these histones within the 
nucleosome profoundly influences the architecture of chromatin. Histone acetylation occurs in 
a steady state equilibrium determined by the relative activity of acetylases and deacetylases at 
a given lysine residue. Histone acetylation occurs at the ɛ amino group of evolutionarily 
conserved lysine residues. The histone acetyl transferases target specific lysine motifs and are 
broadly divided into the nuclear, or Type A, and the cytoplasmic, or Type B (recently reviewed 
in [3]).  
 
Deacetylation is mediated by the classical or TSA-sensitive (Types I and II) HDACs and the 
Type III HDACs or Sirtuins. Class I HDACS [1–3,8] are related to the Saccharomyces 
cerevisiae transcriptional repressor RPD3 and Class II HDACs [4–7,9,20] share homology with 
HDA1. Class I HDACs are primarily nuclear and class II HDACs are dynamically shuttled 
between the nucleus and cytoplasm. Broadly speaking acetylation of histones is associated 
with increased gene expression and reduced compaction of local chromatin. HDACs are 
recruited to DNA in association with co-repressors, via proteins such as methylated CpG-
binding proteins, methyl CpG-binding domain containing proteins and via DNA methyl 
transferases.  
 
The catalytic domain of an HDAC is formed by a stretch of approximately 390 amino acids. 
Deacetylation involves a charge relay system and several essential cofactors to remove acetyl 
groups from the lysine residues. These essential cofactors include Zn
+2
.  HDACs form 
multiprotein complexes, many of which contain nuclear receptor binding proteins, mSin3A, N-
CoR and SMRT [4].  
 
The NAD-dependent HDACs are members of the conserved SIRT family. SIRT1 is a human 
homolog of the yeast HDAC silent information regulator 2 (Sir2). This sirtuin family is 
conserved from archaebacteria to eukaryotes [5,6]. SIRT1 is one of seven human SIRT [6]. 
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SIRT1 couples the removal of the acetyl group from its protein substrate with the cleavage of a 
high-energy bond in NAD, thus synthesizing the novel products 2′- and 3-O-acetyl-ADP-ribose 
[7]. These products are thought to function as secondary messengers. The SIRT1 enzyme is in 
turn inhibited by nicotinamade which, as a metabolic product serves to coordinate intracellular 
metabolism with the activity of SIRT1. In C. elegans and in mice the Sirtuins regulate the 
Insulin/IGF1 signaling axis. In Saccharomyces cerevisiae, SIR2 extends the replicative lifespan 
[8].In C. Elegans increased dosage of the worm SIR2-1 gene extends the lifespan of mother 
cells after caloric restriction [9,10]. In recent studies, deletion of the SIRT6 gene resulted in 
mice with lordokyphosis, defective base-excision repair, severe metabolic defects with reduced 
circulating IGF1 and serum glucose, and premature death [11]. The phenotype of these mice, 
interpreted as an acute degenerative aging like phenotype is considered evidence for a role of 
mammalian SIRT6 in aging [12]. 
  
SIRT1 is thought to deacetylate histones, DNA Polß, the coactivator p300, and several 
downstream transcription factors [11,13]. It has been suggested that the deacetylation of Polß 
by SIRT6 contributes to the defect in base-excision repair of SIRT6
−/− 
Mice. The deacetylation 
of p300 has been linked to the ability of SIRT1 to regulate several transcription factors [13]. 
Given the importance of p300 in NR function, it is important to consider the role of SIRT1 in 
governing p300 function.  
 
The coactivators p300 and its related ortholog CBP are transcriptional integrators regulating 
NR function. The relative abundance of p300 is considered rate-limiting in diverse signaling 
pathways involved in metabolism and cellular differentiation [14]. The coordination of these 
activities involves a scaffold function of the protein to tether transcription factors to the basal 
transcription apparatus, and both an intrinsic and associated histone acetyltransferase activity 
which modifies local chromatin to thereby alter access of transcription factors to their cognate 
DNA binding site. In addition p300 directly acetylates transcription factors and thereby modifies 
their function. The modular structure of p300 facilitates these diverse functions through distinct 
domains. The bromo domain regulates protein-protein interactions and facilitates association 
with chromatin. Three cysteine histidine rich domains (CH) serve as docking modules for 
transcription factors and the glutamine rich carboxyl terminus interacts with the NR 
coactivators, including the steroid receptor coactivators. Located between the amino acids 
1004 and 1044 in p300 is a domain referred to as the CRD (cell cycle regulatory domain). This 
domain was so named based on evidence that that his domain was a target of p21
CIP1 
activity. 
Recent studies however identified the CRD1 domain as the key site of p300 sumoylation [15]. 
As several transcription factors, known to be repressed by SIRT1 were also known to be 
activated by p300, Bouras et al. examined the role of SIRT1 in regulating p300 activity [13]. 
SIRT1 was shown to repress p300 in an NAD-deacetylase dependent manner. SIRT1 
repression of p300 involved the CRD1 domain. Two lysine residues were identified within the 
p300 CRD1 domain that were required for SIRT1 repression. p300 was shown to function as a 
substrate for SIRT1-mediated deacetylation in vitro and by proteomic analysis. The lysine 
residues shown to function as substrates within p300 for SIRT1-mediated deacetylation also 
functioned as acceptor sites for SUMO [13]. The SUMO specific protease SSP3 antagonized 
SIRT1-mediated repression of p300. Because p300 is a limiting coactivator for many 
transcription factors, it is likely that the deacetylation and repression of p300 by SIRT1 may 
integrate metabolic signals within the cell to in turn regulate the diverse metabolic process 
regulated by transcription factors and nuclear receptors.  
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Several transcription factors have been identified as targets of SIRT1. Lysine residues of p53 
[16,17], MyoD, FOXO [18–20], and TAF168 [21] are all targets of hSIRT1. The effect of Sirt1 
on cellular proliferation and growth appears to be cell type specific. Sir2-dependent 
deacetylation of p53 repressed its function, thus promoting cell growth [16,17,22]. In contrast, 
SIRT1 profoundly inhibits prostate cellular proliferation, and does so in a manner dependent 
upon the presence of the androgen receptor [23]. SIRT1 has been found to specifically interact 
with the AR and PPARƴ . Indirect evidence also suggests the ERα may be regulated by 
endogenous SIRT activity.  
2. Nuclear receptors  
2.1. Estrogen receptor  
Estrogen and progesterone receptors (ER and PR) have now been studied in clinical breast 
cancer for more than 20 years [24]. Estrogen receptors are intracellular proteins that can bind 
with estrogens, phytoestrogens, or xenoestrogens. States of increased exposure to serum 
levels of estradiol [25], including early menarche, late menopause, and late or no pregnancies, 
which increase activation of the estrogen receptor in breast tissue, are risk factors for the 
development of breast cancer. This increased activation of the estrogen receptor leads to 
increased cell proliferation and is thought to lead to the progression of abnormal growth of 
breast tissue.  
 
The estrogen receptor (ER) exists in two isoforms: ERα and ERß. Despite their considerable 
homology, these two receptor isoforms have important structural and functional differences that 
are important for tissue and promoter-specific regulation of gene expression, and likely 
contribute to hormonal sensitivity and resistance. The ER is a modular transcription factor with 
functional domains that are conserved between the receptor superfamily members. 
Posttranslational modification by phosphorylation, acetylation and ubiquitination modulate 
ERα activity and subcellular localization in response to hormonal and growth factor signals.  
 
Currently, only ERα has an established clinical role as it predicts the likely response of a 
patient to hormone treatment, both in the adjuvant and metastatic breast cancer setting. 
Patients with breast cancers expressing ERα are approximately seven to eight times more 
likely to benefit from endocrine therapy than ERα -negative patients. For the initial three to five 
years after primary diagnosis, ERα-positive patients generally have a better outcome than 
ERα-negative patients, even if mutant for the BRAC1 gene [26]. Overall, however, the 
prognostic value of ERα is relatively weak and only of limited value in the clinically important 
subgroup of patients with lymph node-negative disease. Further work is required to establish if 
ERß has a clinical role in breast cancer. Additionally, the probability of objective response to 
the endocrine therapy increases with an increase in the quantity of estrogen receptor in the 
cancer [24].  
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Selective estrogen receptor modulators (SERMs) take advantage of the ER activity of breast 
cancers. Currently available agents include, Tamoxifen (Nolvadex), Raloxifene (Evista) and 
Toremifene (Fareston). For the past twenty years, Tamoxifen has been used to treat ER 
positive tumors in the adjuvant and metastatic setting. Results of the Study of Tamoxifen and 
Ralozifene (STAR) trial, will likely see the introduction of Raloxifene into this algorithm. 
Toremifene is not currently available in the United States. The data currently available suggest 
that receptor assays carried out on the primary tumor can be used for prediction of subsequent 
response to the endocrine therapy, even at a later time of recurrent disease. It is well accepted 
that ERα expression level in breast cancer patients not only correlates with higher response to 
hormone therapy but also a better prognosis. Positive receptor status is associated with 
favorable prognostic features including a lower rate of cell proliferation and histologic evidence 
of tumor differentiation. Finally, prognosis can be predicted from the presence or absence of 
estrogen receptor expression. While sequential assays of receptors in lesions from the same 
patients are likely to be in agreement, when changes occur they tend to be reductions in 
amount of receptor or loss of receptor during disease progression. A loss of ERα expression 
portends a poor prognosis as these cells can now grow independently of estrogen regulation 
and have gained resistant to endocrine inactivation therapy [27].  ERα expression status is an 
important biomarker that helps physicians individualize systemic therapy. However, a 
significant number of breast cancers lose expression of the ER gene due to gene silencing by 
a combination of DNA methylation and/or histone deacetylation.  
 
Recently, several studies have focused on the posttranslational modification of ERα. It has 
been shown that ERα is directly acetylated by the coactivator p300 at the well-conserved lysine 
residues in the hinge/ligand domain [28]. The lysine motif was well conserved between nuclear 
receptors. In subsequent studies the lysine motif in other nuclear receptors has been shown to 
function as a target of histone acetylases as predicted in this original study. The histone acetyl 
transferase P/CAF bound to the ERα, and binding required the HAT domain [28]. However 
P/CAF failed to acetylate the ERα while readily acetylating histone. This finding illustrated the 
specificity of interaction between HATs and their NR substrates. A comparison of ERα and 
histone in careful dose-response curves demonstrated that the ERα peptide served as an 
excellent substrate for p300 HAT activity, not dissimilar to histones. Proteomic analysis, 
including Edman degradation assays, identified lysine 302 and 303 as the preferential sites for 
acetylation by p300, with an additional site at lysine 299.  
 
When lysine residues 302 or 303 were mutated to arginine or glutamine, the ERα had 
increased estradiol-dependent activation, suggesting a role for ERα acetylation in ligand 
sensitivity [28] (Fig. 2A). Independent clinical studies, identified the lysine residue as frequently 
a site for mutation [29].In 34% of atypical breast hyperplasia samples, a Lys-to-Arg substitution 
was found at residue 303 (K303R) of the ERα [29]. Expression of this mutant led to a 
hypersensitivity to estradiol, showing maximal stimulation at physiologic levels. In the presence 
of the p160 coactivator and p300 the ERα was shown to be acetylated at lysines 266 and 268 
[30]. In previous studies, an ERα fragment from aa 1-282 was not acetylated by p300 alone, 
suggesting an important independent role for SRC1 in acetylation of aa 266 and 268. The 
finding that the ERα is acetylated at multiple different sites by distinct complexes is not 
surprising and is consistent with analysis of other transcription factors such as p53 [31]. 
p300/CBP acetylates carboxyl-terminal lysine residues of p53 (lysines 372, 373 and 382). DNA 
damage induces acetylation of lysine 320 and lysine 373 with distinguishable kinetics and 
these two residues regulate distinct clusters of genes. The high affinity p53 binding site 
 
This is the author’s final version prior to publication in Steroids 72(2):221-230, February 2007.  The published 
version is available at http://dx.doi.org/10.1016/j.steroids.2006.12.001. Copyright © Elsevier Inc.  All rights 
reserved. 
promotes cell survival [31] and K373 regulates interactions with DNA binding sites of 
proapoptotic genes leading to cell death. Original studies had shown, using anti-acetyl lysine 
antibody-mediated immune precipitation, that the ERα is acetylated in human breast cancer 
cell lines [28]. It will be of interest to determine, using proteomic analysis, which additional 
residues of the ERα are acetylated in vivo.  
 
Several previous studies have demonstrated the role of TSA-dependent HDACs in regulating 
ERα activity. Recent studies of NR have shown a role for NAD-dependent histone 
deacetylases in regulating AR and ERα function. The studies of AR in cultured cells were direct 
and used expression vectors encoding wild type or catalytically defective SIRT1 [23]. The 
SIRT1 activator, resveratrol, led to the inhibition of estrogen-dependent cell proliferation [32] 
providing indirect support for a role of SIRT in regulating ERα activity. In vitro experiments 
showed that the addition of recombinant SIRT1, along with nicotinamide adenine dinucleotide 
(NAD
+
), with ERα, led to a strong deacetylation of the receptor [30]. However, the addition of 
nicotinamide, a known SIRT1 inhibitor, prevented the deacetylation. These lines of study imply 
that SIRT1, by deacetylating ERα, could become a novel therapeutic target for breast cancer, 
as SIRT1 activation could lead to modifications of estrogen signaling that would be beneficial to 
decreasing the proliferation of abnormal breast tissue.  
2.2. Androgen receptor  
2.2.1. Prostate cancer and androgen receptor  
Prostate cancer is the most frequently diagnosed cancer in men in the United States and the 
second leading cause of male cancer deaths [33,34]. The androgen receptor’s function is a 
critical determinant of human prostate cancer pathogenesis and progression. The growth of 
prostate cancer is androgen-sensitive and these growth signals initially go through the AR. 
Current androgen ablation therapy (AAT) remains a major therapeutic intervention in 
metastatic disease, resulting in 60–80% initial response rates. However, prostate cancer 
unresponsive to androgen ablation therapy subsequently emerges in the majority of patients 
resulting in short survival time. AR mutations are frequently associated with AAT resistant 
tumors. The AR is involved in both differentiation and proliferation as specific mutations in the 
AR can selectively affect either differentiation (AR insensitivity) or proliferation.  
2.2.2. Androgen receptor hyperactivity, acetylation and deacetylation  
 
Therapies directed at the AR initially work in a majority of patients with prostate cancer, but 
many develop resistance over time. Hyperactivity of AR expression or function is seen in >20–
30% of prostate cancers. Activated growth factor signaling, loss of tumor suppressors, altered 
coactivator expression and increased AR expression may contribute to prostate tumorigenesis 
in different patients. Posttranslational modification of the AR contributes to enhanced activation 
of the AR. The AR is acetylated in response to physiological stimuli including DHT and 
bombesin [35,36] (Fig. 2B). Modification by acetylation enhances AR transactivation function at 
a subset of target promoters [37], in particular those cell cycle control genes that induce 
cellular proliferation.  
 
The AR is acetylated at a conserved lysine motif. Edman degradation and sequence analysis 
identified the individual residues preferentially acetylated as lysine 630 and 632 with additional 
acetylation at lysine 633. Gain of function mutations of the acetylated lysine residues within the 
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AR, either glutamine or threonine substitutions, enhance DHT-dependent gene transcription at 
androgen-responsive gene promoters [35,38,39]. Conversely small polar substitutions (arginine 
or alanine mutations), reduced ligand-dependent transactivation. Gain-of-function mutants 
demonstrated enhanced cellular growth properties in prostate cancer cells, enhanced cellular 
proliferation and colony size in soft agar [38,39] (Fig. 1). Prostate cancer cells expressing 
acetylation mimic mutants were resistant to their androgen antagonist flutamide [38]. When 
implanted in nude mice human prostate cancer cells expressing either wild type AR or single 
residue point substitutions that function as acetylation mimic mutants demonstrated a dramatic 
enhancement of tumor growth in vivo [38]. Collectively these studies demonstrated for the first 
time that acetylation of a transcription factor, like phosphorylation, directly regulated cellular 
growth.  
 
Analysis of the mechanisms by which AR regulated cellular growth showed reduced apoptosis 
in prostate cancer cells expressing AR acetylation mimic mutants [38]. It is known that AR 
mediated apoptosis involves a JNK-mediated pathway and that AR acetylation mimic mutants 
evade JNK-mediated apoptosis [38]. In addition AR acetylation mimic mutant expression was 
associated with enhanced cellular proliferation and Ki67 staining in cells. The AR acetylation 
site was shown to regulate transactivation but did not affect several other functions of the AR 
including transrepression, sumoylation or protein stability (Fig. 2). When expressed at 
physiological levels, the AR acetylation site did not affect protein abundance or subcellular 
distribution in prostate cancer cells. Superphysiological expression of the AR acetylation dead 
mutants in Hela cells appeared to increase the rate of nuclear translocation in response to 
androgen, increase the nuclear exclusion in the absence of ligand, and reduce the completion 
of nuclear translocation of the mutant associated with the formation of cellular aggregates [40]. 
It will be of interest to determine whether the acetylation site plays a role in disease states 
associated with misfolded proteins.  
Investigation of the multiprotein complex recruited to the AR in a manner dependent upon the 
acetylation site, demonstrated that the lysine residues regulated recruitment and 
coprecipitation of p300. The charge of the lysine residues directly affected the biochemical 
association with p300 in vitro, and in cultured cells. Conversely the enhanced association with 
p300 correlated with reduced binding of an NCoR/HDAC/Smad3/Sin3A complex in cultured 
cells. These studies suggested the AR acetylation site regulates cellular growth through 
recruitment of HDAC/NCoR/Smad complexes to the promoters of a subset of cell-cycle 
regulatory genes, including cyclin D1 [23].  
 
The AR acetylation and phosphorylation are functionally linked, with the AR acetylation site 
governing cAMP and AKT, but not ERK-induced AR activity [37]. In prostate cancer cell lines, 
the AR is phosphorylated and dephosphorylation inhibits AR activity. Activation of the cAMP 
pathway leads to a rapid dephosphorylation of the AR likely through induction of PKA inducible 
phosphatases. Activity of the AR is enhanced by induction of the MAPK pathway. Mutation of 
the lysine residues reduced ligand induced phosphorylation [37]. Conversely point mutation of 
phosphorylation sites in the AR reduced HDAC-mediated regulation of the AR. Together these 
studies demonstrated that the AR phosphorylation and acetylation events are linked.  
 
Recent studies demonstrated that AR function is regulated by the NAD-dependent histone 
deacetylases (SIRT1) [42]. Sirt1 was shown to colocalize in nuclear cord like structures with 
the AR. Addition of the SIRT1 inhibitor nicotinamide induced androgen-regulated gene 
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transcription. SIRT1 was found to bind directly to the AR and the association was regulated by 
DHT. Sirt1 expression inhibited AR activity, requiring the catalytic activity of SIRT1. A point 
mutation of the core histidine residue of SIRT1, which abrogates its deacetylase activity, also 
reversed the repression of androgen receptor signaling [13,19]. SIRT1 was also found to inhibit 
the contact-independent growth stimulated by AR-expressing cancer cells. Sirt1 inhibited the 
activity of the AR in cultured cells and inhibited activating mutants of the AR identified in 
patients with resistance to current prostate cancer therapy. These AR mutants, which arise in 
the ligand binding domain, were readily repressed by Sirt1, however a single point substitution 
in the AR acetylation site evaded Sirt1-mediated repression. Growth suppression of prostate 
cancer cellular growth by Sirt1 was observed in cells expressing the AR, but not in cells that 
failed to express the AR. Sirt1 expression and function is regulated by dehydrotestosterone 
(DHT) and local metabolism suggesting SIRT1 may function as a physiological regulator of AR 
function.  
 
Recent studies have shown alterations in histone acetylation occur in patients with prostate 
cancer [43], Histone modification patterns predicted tumor recurrence independently of tumor 
stage, preoperative PSA and capsule invasion [43]. A number of studies have shown metabolic 
changes occur with tumor progression in prostate cancer, with increased lactate level occurring 
with tumor grade progression [44,45]. During prostate cancer progression, metabolism shifts 
towards cytosolic glycolysis, which results in increased production of lactate. As SIRT1 activity 
is NAD-dependent, and because lactate decreases the NAD/NADH ratio, the dependence of 
cancer cell on glycolysis and thus lactate production [19,46] could also inhibit the function of 
SIRT1 in vivo and thereby enhance AR function. Since Sirt function is induced by lactate it will 
be of interest to determine whether the alteration in metabolism that occurs in prostate cancer 
contribute to the alterations in global chromatin structure and thereby deregulated gene 
expression that occurs in prostate cancer tumor progression.  
 
2.2.3. SIRT1 as a novel therapy target  
 
Although several distinct substrates for SIRT1 have been identified, (e.g., acetylated lysine 
residues of p53 and FOXO [6]), the dominant effect of Sirt1 in prostate cancer cell lines is to 
inhibit prostate cancer cellular proliferation in an AR-dependent manner [42]. Structural 
analysis of the AR/Sirt1 complex has been described. The minimized structure of the 
hSIRT1/AR peptide/NAD complex was modeled using the molecular display program Chimera 
from the University of San Francisco (Fig. 3). In this model the KLKK peptide (yellow) and the 
NAD molecule (cyan) is shown as “a ball and stick model”. The hydrophobic part of the lysine 
K630 side chain packs favorably against the aromatic ring in the side chain of F309 (Fig. 3). 
Determination of the molecular mechanism of the SIRT1/AR interaction and its physiologic 
effect on the function of the AR mutants that arise in patients with androgen ablation therapy 
resistant tumors may lead to the identification of a novel and effective new prostate cancer 
therapy. Collectively these studies of the AR have led to a working model in which the AR is 
bound to co-repressors in the absence of ligand, including HDAC and Sirt (Fig. 4). The 
derepression, of AR activity by addition of ligand induces AR activity in a manner that is 
dependent upon the AR acetylation site (Fig. 4).  
2.3. Peroxisome proliferator-activating receptor  ƴ  
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Peroxisome proliferator-activating receptor ƴ (PPARƴ ) mediates adipocyte differentiation, 
insulin sensitivity and inhibits cellular proliferation. PPARƴ  functions in either ligand-
dependent or ligand-independent manner. Upon ligand binding, PPARƴ  interacts with several 
coactivators (CBP, p300, SRC-1, PRIP, Med220) for transcriptional activation and in the 
absence of ligand, complexes with PGC-1, or N-CoR, SMRT, or HDAC3. PPARƴ  ligands 
inhibit growth of several types of cancer cells, including breast, gastric adenocarcinoma, 
thyroid, lung, and colon cancer. PPARƴ  is expressed in both colon epithelial cells as well as 
colon cancer cells, and may function early to block of colon cancer progression [47] which is 
inactivated by increased expression of cyclin D1 [48,41,49]. The PPARƴ  ligand, troglitazone, 
induced apoptosis of thyroid papillary cancer cells [50] and the PPARƴ  ligand rosiglitazone 
partially reversed the mesenchymal-to-epithelial change in anaplastic thyroid cancer [51].   
PPARƴ  decreased cell proliferation in both breast and non-small cell lung cancer [52]. In 
some studies in transgenic mice however PPARƴ  activation functions as a collaborative 
oncogene rather than a tumor suppressor [53]. Resolving the question of whether PPARƴ  is a 
tumor suppressor in the breast needs to be resolved, given the millions of patients taking 
PPARƴ  agonists for non-insulin dependent diabetes [53].  
 
PPARƴ  regulates the expression of cyclin D1 through association of HATs and HDACs [48], 
SIRT1 regulates lipid metabolism through PPARƴ  [6,13,54].PPAR is repressed by SIRT1 
and upon starvation in mice, PPARƴ -regulated genes are repressed by SIRT1, causing fat 
mobilization in adipocytes. These studies imply that downregulation of PPARƴ activity by 
pharmacological activation of SIRT1 might be beneficial for obesity. Given the importance of 
NR acetylation in their growth function, the mechanism by which Sirt1 regulates PPARƴ  
function, either indirectly through co-activators, or directly, may be of interest in developing new 
compounds to modulate PPARƴ growth function.  
3. Conclusion  
The androgen receptor is a well defined traditional target for the chemotherapy of prostate 
cancer. The deacetylation of the AR by SIRT1 may provide an alternative approach to 
inactivating the AR to benefit patients with prostate cancer. The functional activity of ERα is an 
important promoter of human breast cancer, and is regulated by acetylation. Discovering the 
exact role of ERα acetylation and the deacetylation caused by SIRT1 may also lead to new 
therapies for ERα positive cancer. Finally, PPARƴ , known to be involved in several cancer 
types, associates with both HATs and HDACs. Modification of nuclear receptors by acetylation 
provides an important new target for therapeutic intervention in disease states driven by 
abnormal nuclear receptor function.  
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Fig. 1 – The AR acetylation mutants conveys contact-independent growth. (Aa and b)  
The human prostate cancer DU145 cells, stably expressing the ARwt or AR acetylation site 
mutants, were seeded in soft agar. The AR acetylation site mutants (ARK630Q and ARK630T) 
represent gain of function mutants that function as acetylation mimics. Phase contrast image of 
the colonies from a representative experiment is shown (100×). Colony numbers and size 
(percentage of colonies with more than 100 cells) determined on day 14. Compared with the 
ARwt, the AR acetylation site point mutant mimics dramatically enhance the size of the 
colonies. (Ba and b) Nude mice were implanted with 1 × 10
6 
cells of stable lines expressing 
either the ARwt or AR acetylation site mutants. Mean volume of DU145 tumors grown in nude 
mice are shown at each time point (From Fu et al., 2003, with permission) [39]. Collectively 
these studies demonstrate that a single amino acid residue substitution of the AR acetylation 
site enhances the growth function of the human AR in human prostate cancer cell lines.  
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Fig. 2 – Acetylation of the ER and AR are regulated by both TSA and NAD sensitive 
histone deacetylases.  
ERα and AR share conserved lysine residues that are acetylated by distinct HATs (reproduced 
with permission from [55]). The ERα is shown associated with the BRCA1 protein, which is 
known to repress activity of the ERα [56,57]. The two known acetylation sites of the ERα and 
their amino acid sequence is shown. p300 is a coactivator of the ERα and the AR. SIRT1 is 
known to deacetylate and thereby repress the activity of p300 [13]. The ERα may be a target of 
SIRT1 as chemical inhibitors of SIRT1 regulate ERα activity. The acetylation site of the ERα 
has been shown to govern several functions [29] (transactivation, DNA synthesis, apoptosis, 
BRCA1 repression). (B) The AR acetylation site is shown as a substrate for p300 acetylation 
and for deacetylation by SIRT1-Acetylation of the AR has been shown to regulate several key 
functions of the AR (DNA synthesis, transactivation, and cellular growth [35,37,39,58] but does 
not affect AR-mediated transrepression or sumoylation.  
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Figure 3 – Homology model of AR-“KLKK” peptide with NAD bound SIRT1.   
The structure of the hSirT1 and AR “KLKK” peptide-NAD complex is shown as the ribbon 
model generated using the molecular display program CHIMERA.  The “KKK” peptide (yellow) 
and the NAD molecule (cyan) are shown as the “ball-and-stick” model. 
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Fig. 4 – (A) Schematic representation of AR bound to corepressors in the absence of 
ligand in the context of local chromatin, dependent in part upon the AR lysine motif.  
SIRT1 inhibits AR activity. SIRT1 is shown to associate with the NCoR/HDAC repression 
complex. (B) Upon the addition of ligand (DHT), disengagement of the corepressor complex 
and recruitment of the coactivator complex engages gene expression, dependent in part upon 
the AR lysine motif.  
 
 
